Acticor Biotech: towards receivership

(CercleFinance.com) - Acticor Biotech announced last night that it had filed a petition to convert the company's insolvency proceedings into a judicial liquidation.


The petition to the Paris Commercial Court will be examined at a hearing scheduled for December 19.

In October, the company, which specializes in the treatment of stroke, was granted an extension by the courts to find new investors or a buyer.

Following the failure, last July, of its phase 2/3 trial in the treatment of mechanical thrombectomy in acute ischemic stroke, Acticor had declared that it only had a cash flow horizon until January 2025.

On the Paris stock exchange, the share price was suspended pending the next steps in the proceedings.

Copyright (c) 2024 CercleFinance.com. All rights reserved.